11.01.04
The Center for Science in the Public Interest (CSPI), Washington, D.C., recently filed a complaint with the Federal Trade Commission (FTC), Washington, D.C., regarding the deceptive advertising of sexual enhancement supplements, specifically naming a product called Enzyte, which is marketed by Berkeley Premium Nutraceuticals, Cincinnati, OH. And apparently CSPI is not the only organization to take issue with the large supplement marketer. According the CSPI, Berkeley is reportedly under investigation from one state attorney general’s office and the target of two class action lawsuits seeking refunds for Enzyte customers. CSPI’s letter to FTC states, “FTC requires that advertising claims for dietary supplements, including those based on testimonials of users, ‘be backed by sound scientific evidence.’ Berkeley, however, has conceded that it has no scientific studies of Enzyte substantiating any of its claims.” CSPI concluded its letter saying that the overall net impression of the claims in the advertisements for Enzyte indicates that they are clearly deceptive and called for FTC to halt Berkeley’s advertising for the product.